When I read news articles about cancer research, I often find myself annoyed by the confusing way in which terminology about cancer and cancer research in used.
In cancer language, it’s not unusual for the medical or scientific meaning of a word to be different from the way the same word is understood in everyday language.
Two recent studies have come out with some interesting and important findings about exposures to endocrine disrupters and our risks for cancer.
One widely-reported study examined the risks for breast cancer associated with the use of hair dyes, which contain endocrine disrupters.
And another study looked at the way exposures to endocrine disrupters are measured. This study was not as widely publicized, but its findings could potentially be very significant. Continue reading
I always come back from the San Antonio Breast Cancer Symposium overflowing with information and insights about the latest developments in breast cancer research.
This year, we learned about fascinating research in areas such as matching treatments better to individuals based on the molecular characteristics of their cancer and finding more ways to bring immunotherapy into breast cancer treatment. Continue reading
Timely access to treatment is critical for individuals dealing with any number of medical conditions. Metastatic breast cancer is no exception.
The Metastatic Breast Cancer Access to Care Act would waive the lengthy waiting periods that currently prevent individuals with advanced breast cancer from receiving timely access to care. Continue reading
Over the years, October has become a marketing opportunity for companies that splash pink on their products, suggesting to consumers that they’re helping the breast cancer cause by buying these products.
Unfortunately, most of the time very little of the money paid for these products actually goes to breast cancer-related charities. Continue reading
One of the stories that has stood out over the last few years in breast cancer treatment was the FDA’s approval in 2015 of the drug palbociclib (Ibrance) for treatment of hormone receptor-positive metastatic breast cancer.
This year, there have been several new developments in targeted therapies for hormone-receptor positive breast cancer. Continue reading
I’m delighted to participate in the 2019 Summer Blogging Challenge offered by my friend and fellow blogger, Nancy, at Nancy’s Point.
The challenge involves answering a series of random questions about ourselves and blogging. Continue reading
What are the best ideas for how we could prevent breast cancer in whole populations?
This was the big question behind a recent competition sponsored by the California Breast Cancer Research Program. Continue reading
One of my first posts here on After Twenty Years in 2013 was a look back at progress against breast cancer in the twenty years since I had been diagnosed.
Now, let’s take another look back, but this time we’ll focus on what we’ve seen in progress against breast cancer over the last five years or so. Continue reading
Earlier this month, the long-awaited results of the TAILORx clinical trial were announced.
The findings from this study are important for early stage breast cancer patients with hormone receptor-positive breast cancer. The study results are expected to assist many patients in this group in determining whether chemotherapy should be part of their treatment. Continue reading
